Noncompliance is an important problem in randomized trials. The estimation and bounds of average causal effects (ACEs) have been discussed as a way to address this issue. Previous studies have considered ACEs under the instrumental variable (IV) assumption, which postulates that potential outcomes are constant across subject sub-populations assigned to separate treatment regimens. However, the IV assumption may not be valid in unmasked trials. In the present analyses, the IV assumption is relaxed to the monotone IV (MIV) assumption, which replaces equality in the IV assumption with inequality. We propose bounds on ACEs under the MIV assumption in addition to the other existing assumptions. The results demonstrate that the intention-to-treat effect is an upper or lower bound under one assumption and the per-protocol effect is an upper or lower bound under the other assumption, even using the MIV assumption in place of the IV assumption. These proposed bounds are illustrated using a classic randomized trial.
Introduction
In human clinical trials, ethical considerations pertaining to study subjects override a study's scientific requirements. One resource for coping with the inevitable trial-associated subject noncompliance is intention-to-treat (ITT) analysis. In ITT analysis, the parameter estimates are not affected by noncompliance, as subjects are analyzed according to the assigned treatment rather than the treatment actually received (Lee et al., 1991) . However, although the ITT estimate may represent the effect of a treatment policy, it generally does not estimate the causal effect of a treatment in an unbiased manner (Sheiner and Rubin, 1995) , where the causal effect is a comparison between the expected outcome if the subjects had received a test treatment versus that if they had received the control treatment.
As summarized in a recent review by Sato (2006) , estimation of causal effects has been discussed by several researchers. These discussions have covered two types of causal effects:
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This assumption indeed replaces equality with inequality in the IV assumption, and means that the values of potential outcomes for subjects assigned to R = 1 are larger than those assigned to R = 0 on average. For example, consider an unmasked trial to compare a new treatment with a standard treatment, where the outcome is a measure such that a larger value is better for the subject's health. In such a trial, subjects may think that the new treatment is more effective than the standard treatment, and this thinking may give rise to better results for subjects assigned to the new treatment than those assigned to the standard treatment. Then, the values of potential outcomes for subjects assigned to a new treatment (R = 1) may be larger than those for subjects assigned to a standard treatment (R = 0) on average; this implies that
When the outcome Y has finite range [K0, K1], the bounds on the ACE under the MIV are as follows:
The derivation of this inequality is presented in Appendix A. Note that inequality (1) is a binary treatment version of the result from Manski and Pepper (2000, 2009) , and K0 = 0 and K1 = 1 in the case of a binary outcome.
Using the inverse sign of the inequality in the MIV, the following inverse MIV (IMIV) assumption is applied:
In contrast to the MIV, the IMIV means that the values of potential outcomes for subjects assigned to R = 1 are smaller than those assigned to R = 0 on average. This may hold when the lower value of an outcome is better for subjects' health in the same comparison of treatments as the above example for the MIV.
The bounds on the ACE under the IMIV are
The derivation of this inequality is similar to that presented for inequality (1).
The monotone treatment response assumption
Manski (1997) has previously presented the monotone treatment response (MTR) assumption.
In the setting of a binary treatment, this assumption is formally presented as follows:
The MTR means that a subject ω takes a larger value of outcome if ω received the test treatment than if ω received the control treatment, and holds when it is apparent that an exposure (treatment) has a positive effect. An outstanding example of this assumption is the influence of smoking (X) on lung cancer (Y ). It is well known that smoking is an important prognostic factor of lung cancer, and the potential occurrence of lung cancer if one smoked (X = 1) is higher than that if one had not smoked (X = 0) for all individuals; this implies that
By combining the MTR with the MIV, the lower bound on the ACE is improved as follows:
where 
YX=0(ω).
The IMTR means that a subject ω takes a smaller value of outcome if ω received the test treatment than if ω received the control treatment, and holds when it is apparent that an exposure (treatment) has a negative effect. Again, consider the example of the influence of smoking (X) on lung cancer (Y ). When subjects are smokers, the potential occurrence of lung cancer if one quits smoking (X = 1) is lower than that if one continues to smoke (X = 0) for all
individuals; this implies that YX=1(ω) ≤ YX=0(ω).
Each combination of the MIV or IMIV and the MTR or IMTR can be used to improve the lower or upper bound on the ACE. The results are as follows:
Under the IMIV + IMTS, ACE ≥ PP,
The derivation of these inequalities is similar to that presented for inequality (3).
The results presented in Sections 3.2 and 3.3 above imply that both the lower and upper bounds can be improved under some combinations of the MTR or IMTR and the MTS or IMTS in addition to the MIV or IMIV. These improved bounds are summarized in Table 1 . 
Assumptions Bounds on ACE
Application
For illustration, the bounds presented in Section 3 are applied to data from the Multiple Risk Factor Intervention Trial (MRFIT) (MRFIT Research Group, 1982) . The MRFIT was a large field trial to test the effect of a multifactor intervention program on mortality from coronary heart disease (CHD) in middle-aged men with sufficiently high risk levels attributed to cigarette smoking, high serum cholesterol, and high blood pressure. The intervention consisted of dietary advice on ways to reduce blood cholesterol, smoking cessation counseling, and hypertension medication. All subjects were randomly assigned to the intervention program or the control group.
For this illustration, attention is restricted to the effects of cessation of cigarette smoking.
This restriction follows other studies (Sato, 2000; Matsui, 2005 ) and was applied due to the paucity of differences achieved for the other risk factors. Table 2 summarizes the incidence of subject mortality due to CHD during the 7-year follow-up based on the assigned treatment and the actual subject smoking status 1 year after study entry. Analytical interest focused on the ACE, defined as the causal effect of quitting smoking on CHD deaths among all participants, rather than the CACE, which is the causal effect among the subpopulation of potential compliers.
In the calculations, R represents the assigned group (R = 1 for the test group and R = 0 for the control group), X is the actual smoking status 1 year after entry (X = 1 for smoking cessation and X = 0 for continued smoking), and Y is the incidence of CHD deaths (Y = 1 for dead and Y = 0 for alive). To derive the ACE bounds, it is necessary to discuss whether the assumptions in Section 3 hold. In the MRFIT, subjects would have been aware of their assigned group, since this was an unmasked trial, so the intervention itself might have evoked a psychological response. Furthermore, in addition to smoking cessation counseling, the intervention consisted of dietary advice for the reduction of blood cholesterol and hypertension medication. These interventions might have directly influenced the incidence of CHD independent of smoking status. Therefore, on average, the potential incidence of CHD for subjects assigned to the test group might have been reduced as compared with subjects assigned to the control group. This observation implies that the validity of the IV assumption is questionable, but that the IMIV assumption,
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, is reasonable. It is also obvious that cessation of cigarette smoking can prevent death from CHD. Thus, the IMTR assumption, YX=1(ω) ≤ YX=0(ω) for each ω, holds.
In general, health-conscious individuals may tend not to die from CHD and to quit smoking as compared with persons who are not oriented towards health considerations. Trial subjects would likely have had similar tendencies, and subjects who did quit smoking would logically tend not to have died from CHD. Therefore, it is considered that the IMTS assumption, E(YX=x | X = 1, R = r) ≤ E(YX=x | X = 0, R = r) for x = 0, 1 and r = 0, 1, is valid.
The arguments presented above demonstrate that the IMIV, IMTR, and IMTS can be assumed. Therefore, from Table 1 
Discussion
This report proposes bounds on ACE in randomized trials with noncompliance. Whereas previous studies have required the IV assumption, the analytical approach outlined above does not require this assumption. Instead, calculations utilize the MIV assumption, which replaces equality in the IV assumption with inequality. Although the results presented above are relevant to the causal differences, they can also be readily applied to the causal risk ratio when the outcome is binary.
It is generally thought that the ITT analysis is likely to yield a downwardly biased estimate of causal effects (Sheiner and Rubin, 1995) , whereas the PP analysis is likely to yield an upwardly biased estimate (Lewis and Machine, 1993) . Thus, the ACE probably exists between the results of the ITT and PP analyses. While this is true under IV + MTR + MTS or under IV + IMTR + IMTS (Chiba, 2009), we cannot be certain that it is true when the IV assumption does not hold. As is evident from the results presented in Table 1 , one bound is the ITT or PP effect, and another bound is not one of these effects. Therefore, investigators should not simply conclude that the ACE exists between the results of the ITT and PP analyses.
No standard method for estimating the ACE in randomized trials with noncompliance issues currently exists. Investigators should consider whether the assumptions presented in this report are valid and then yield the bounds on the ACE using the methodology described herein. Further methodological researches are needed for answering to these issues.
The appendix outlines the derivation of inequalities (1)
-(3).
A. The derivation of inequality (1) E(YX=x) is transformed as
Therefore, under the MIV assumption, E(YX=x | R = 1) ≥ E(YX=x | R = 0) for x = 0, 1, the following inequality holds:
and similarly
Using them, the lower bound of E(YX=1) becomes
and the upper bound of E(YX=1) becomes
The similar calculations for E(YX=0) yield the lower bounds of The lower bound on ACE=E(YX=1)−E(YX=0) is derived from {the lower bound of E(YX=1)} minus {the upper bound of E(YX=0)}, and the upper bound on ACE is derived from {the upper bound of E(YX=1)} minus {the lower bound of E(YX=0)}. These differences derive inequality
(1).
B. The derivation of inequality (2)
The MTR 
